Roles of p85, Ras, and elF3i/Trip1 in pI3-kinase oncogenic transformation
p85、Ras 和 elF3i/Trip1 在 pI3 激酶致癌转化中的作用
基本信息
- 批准号:7494986
- 负责人:
- 金额:$ 5.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAntineoplastic AgentsBindingBiochemicalBiological AssayBreastCatalytic DomainCell physiologyCellsClassColonEnzymesGTP BindingGenus ColaGoalsGrowthGrowth FactorGrowth Factor ReceptorsHot SpotIn VitroLeadLigandsMalignant NeoplasmsMediatingMembraneMolecularMonomeric GTP-Binding ProteinsMutationOncogenesOncogenicPIK3CA genePathway interactionsPhosphoinositide-3-Kinase, Catalytic, Gamma PolypeptidePhosphotransferasesPhosphotyrosinePlayProkaryotic Initiation Factor-3Protein IsoformsProteomicsProto-Oncogene Proteins c-aktRNA InterferenceReceptor Protein-Tyrosine KinasesRecruitment ActivityRegulationRoleSH3 DomainsSignal PathwaySignal TransductionSolid NeoplasmTestingTranscriptional RegulationTransforming Growth Factor betaTransforming Growth FactorsTranslation InitiationTranslationscell transformationdesigngain of functiongain of function mutationhuman PIK3CA proteinhuman RIPK1 proteinin vivoinhibitor/antagonistinsightknock-downmutantreceptorresearch studytumor progression
项目摘要
DESCRIPTION (provided by applicant): The Pl3-kinase signaling pathway is upregulated in numerous cancers. Hot spot mutations in the catalytic subunit of PI3-kinase, p110 alpha, occur in approximately 30% of several types of solid tumors. The goal of this proposal is to understand the molecular mechanism underlying the oncogenic transformation induced by cancer specific mutant p110 alpha and provide insight into the design of mutant specific inhibitors as anti- cancer drugs. The experiments proposed in this application will make extensive use of retroviral constructs to analyze oncogenic transformation induced by p110 alpha mutants. p85 and Ras have been shown to regulate the kinase activity of p110 alpha. I will examine if oncogenic p110 alpha losses the inhibitory regulation by p85 via in vitro kinase assays and in vivo cell transformation assays. I will determine if the oncogenicity of p110 alpha depends on Ras binding and causes constitutive activation of Ras using biochemical analysis, cell transformation assay, and RNAi. I have identified a new p110 alpha-binding partner, elF3i/Trip1. Here, I will first test the importance of elF3i/Trip1 in PI3-kinase transformation by knocking down elF3i/Trip1, and then investigate the possible impact of oncogenic p110 alpha on translation initiation mediated by elF3i and transcriptional regulation mediated by TGF beta/Tripl pathways.
描述(由申请人提供):P13-激酶信号传导途径在许多癌症中上调。PI 3-激酶催化亚基p110 α的热点突变发生在约30%的几种类型的实体瘤中。该提案的目标是了解癌症特异性突变体p110 α诱导的致癌转化的分子机制,并为突变体特异性抑制剂作为抗癌药物的设计提供见解。本申请中提出的实验将广泛使用逆转录病毒构建体来分析由p110 α突变体诱导的致癌转化。p85和Ras已显示调节p110 α的激酶活性。我将通过体外激酶试验和体内细胞转化试验研究致癌p110 α是否失去了p85的抑制性调节。我将使用生化分析、细胞转化试验和RNAi来确定p110 α的致癌性是否依赖于Ras结合并引起Ras的组成性激活。我已经确定了一个新的p110 α结合伴侣,elF 3 i/Trip 1。在这里,我将首先通过敲低elF 3 i/Trip 1来测试elF 3 i/Trip 1在PI 3激酶转化中的重要性,然后研究致癌p110 α对elF 3 i介导的翻译起始和TGF β/Trip 1通路介导的转录调控的可能影响。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Li Zhao其他文献
Li Zhao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Li Zhao', 18)}}的其他基金
The genetic and epigenetic mechanisms of phenotypic innovationhttps://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
表型创新的遗传和表观遗传机制https://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
- 批准号:
10431835 - 财政年份:2019
- 资助金额:
$ 5.48万 - 项目类别:
The genetic and epigenetic mechanisms of phenotypic innovationhttps://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
表型创新的遗传和表观遗传机制https://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
- 批准号:
10002266 - 财政年份:2019
- 资助金额:
$ 5.48万 - 项目类别:
The genetic and epigenetic mechanisms of phenotypic innovationhttps://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
表型创新的遗传和表观遗传机制https://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
- 批准号:
10624853 - 财政年份:2019
- 资助金额:
$ 5.48万 - 项目类别:
The genetic and epigenetic mechanisms of phenotypic innovationhttps://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
表型创新的遗传和表观遗传机制https://apps.era.nih.gov/gm/reportCheckList.do?applicationID=9798249
- 批准号:
10183272 - 财政年份:2019
- 资助金额:
$ 5.48万 - 项目类别:
Roles of p85, Ras, and elF3i/Trip1 in pI3-kinase oncogenic transformation
p85、Ras 和 elF3i/Trip1 在 pI3 激酶致癌转化中的作用
- 批准号:
7331712 - 财政年份:2007
- 资助金额:
$ 5.48万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 5.48万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 5.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 5.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 5.48万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 5.48万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 5.48万 - 项目类别: